Stability in results of operations characterize Orkuveita Reykjavíkur’s (OR; Reykjavík Energy) consolidated interim financial statements for Q1 2018. The company’s Board of Directors approved the statements today. In addition to the parent company, the OR group comprises Veitur Utilities, ON Power and Reykjavík Fibre Network.

Despite a reduction of water and electricity tariffs, revenues increased in Q1 2018 compared to the previous year. Increased economic activity in Iceland play a part in that and appear for example in increased heating revenues. Fluctuations in the price of aluminum are apparent in calculated values in the interim financial statement. In Q1 2018 the effect was unfavorable by ISK 5.2 billion while in Q1 2017 the effect was favorable by ISK 5.3 billion. However, the result of Q1 2018 was a profit of ISK 390 million.

*A proposal for dividends*

OR’s Board of Directors also approved today a proposal to OR’s general meeting to be held in June for a payment of dividends for year 2017 in the amount of ISK 1,250 million.

*Bjarni Bjarnason, CEO:*

Orkuveita Reykjavíkur’s basic operations are very solid. The interim financial statements reflect increased economic activity in Iceland; revenues increase but also operating cost and we have to stay vigilant. We are developing the basic services the companies within the group provide as can be seen in energy-shift in transportation and the implementation of smart-metering is on the horizon.

*Managers’ Overview*

ISK million * Q1 2015* *Q1 2016* *Q1 2017* *Q1 2018*
Revenues 11,110  11,336  11,822  12,263 
Expenses (3,880) (4,079) (4,138) (4,511)
  thereof energy purchase and transmission (1,868) (1,635) (1,701) (1,730)
         
*EBITDA* *7,230  * *7,257  * *7,685  * *7,752  *
Depreciation (2,399) (2,406) (2,384) (2,287)
*EBIT* *4,831  * *4,850  * *5,301  * *5,464  *
         
*Result of the period* *3,276  * *2,535  * *6,039  * *390  *

 Orkuveita Reykjavíkur's key financial figures

Contact:

Bjarni Bjarnason

CEO

+354 516 6100

*Attachment*

· OR Interim Financial Statements Q1 2018 Reported by GlobeNewswire 3 hours ago.

*NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR **DISSEMINATION IN THE U.S.*

TORONTO, May 28, 2018 (GLOBE NEWSWIRE) -- GPM Metals Inc. (“*GPM*” or the “*Company*“) (TSXV:GPM) is pleased to announce that it proposes to complete a non-brokered private placement (the “*Offering*”) pursuant to which it will issue up to 10,000,000 units (“*Units*”) at a price of $0.05 per Unit to raise aggregate gross proceeds of up to $500,000.  Each Unit shall consist of one common share of the Company (a “*Share*”) and one-half of one share purchase warrant (each whole share purchase warrant, a “*Warrant*”), with each such Warrant exercisable to acquire one additional Share at an exercise price of $0.10 for a period of 24 months from the closing of the Offering.  Insiders of the Company may subscribe for up to 8,000,000 Units in the Offering.

The Offering is currently scheduled to close on or about June 20, 2018 and remains subject to the receipt of all applicable regulatory approvals, including the approval of the TSX Venture Exchange.

For further information please contact:  
Peter Mullens Michael Murphy
Chief Executive Officer General Manager Canada
pjm@gpmmetals.ca  michael.murphy@gpmmetals.ca 
(416) 628-5904  
Email: info@gpmmetals.ca  

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*Forward-Looking Statements

Information set forth in this news release involves forward-looking statements under applicable securities laws. The forward-looking statements contained herein include, but are not limited to, the anticipated size and completion the Offering and the receipt of applicable regulatory approvals, and all such forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although the Company believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct and, accordingly, undue reliance should not be put on such forward-looking statements.  This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. Reported by GlobeNewswire 3 hours ago.

Paris, May 28^th 2018 - 19h00

*COFACE SA: Disclosure of trading in own shares*
*(excluding the liquidity agreement) made between*
*May 21^th and May 25^th 2018*

Pursuant to Regulation (EU) No 596/2014 of 16 April 2014 on market abuse^[1]

The main features of the 2017-2018 Share Buyback Program have been published on the Company's website (http://www.coface.com/Investors/Disclosure-requirements, under "Own share transactions") and are also described in the Registration Document. This information shall be completed with the press release of February 12^th 2018.

*Trading session of (Date)* *Transaction* *Number of shares* *Weighted average price* *Gross amount* *MIC Code* *Purpose of buyback*  
 
21/05/2018 Purchase 363 9.6400 € 3,499.32 € XPAR Cancellation  
21/05/2018 Purchase 288 9.6500 € 2,779.20 € XPAR Cancellation  
21/05/2018 Purchase 9 9.6500 € 86.85 € XPAR Cancellation  
21/05/2018 Purchase 31 9.6500 € 299.15 € XPAR Cancellation  
21/05/2018 Purchase 389 9.7400 € 3,788.86 € XPAR Cancellation  
21/05/2018 Purchase 205 9.7400 € 1,996.70 € XPAR Cancellation  
21/05/2018 Purchase 248 9.7400 € 2,415.52 € XPAR Cancellation  
21/05/2018 Purchase 8 9.7900 € 78.32 € XPAR Cancellation  
21/05/2018 Purchase 353 9.7900 € 3,455.87 € XPAR Cancellation  
21/05/2018 Purchase 200 9.7900 € 1,958.00 € XPAR Cancellation  
21/05/2018 Purchase 151 9.7900 € 1,478.29 € XPAR Cancellation  
21/05/2018 Purchase 440 9.7700 € 4,298.80 € XPAR Cancellation  
21/05/2018 Purchase 461 9.7900 € 4,513.19 € XPAR Cancellation  
21/05/2018 Purchase 39 9.7900 € 381.81 € XPAR Cancellation  
21/05/2018 Purchase 272 9.7900 € 2,662.88 € XPAR Cancellation  
21/05/2018 Purchase 518 9.7600 € 5,055.68 € XPAR Cancellation  
21/05/2018 Purchase 656 9.7300 € 6,382.88 € XPAR Cancellation  
21/05/2018 Purchase 303 9.7300 € 2,948.19 € XPAR Cancellation  
21/05/2018 Purchase 169 9.7600 € 1,649.44 € XPAR Cancellation  
21/05/2018 Purchase 295 9.7600 € 2,879.20 € XPAR Cancellation  
21/05/2018 Purchase 310 9.7600 € 3,025.60 € XPAR Cancellation  
21/05/2018 Purchase 27 9.7600 € 263.52 € XPAR Cancellation  
21/05/2018 Purchase 328 9.7700 € 3,204.56 € XPAR Cancellation  
21/05/2018 Purchase 112 9.7600 € 1,093.12 € XPAR Cancellation  
21/05/2018 Purchase 299 9.7600 € 2,918.24 € XPAR Cancellation  
21/05/2018 Purchase 295 9.7600 € 2,879.20 € XPAR Cancellation  
21/05/2018 Purchase 102 9.7600 € 995.52 € XPAR Cancellation  
21/05/2018 Purchase 317 9.7600 € 3,093.92 € XPAR Cancellation  
21/05/2018 Purchase 128 9.7600 € 1,249.28 € XPAR Cancellation  
21/05/2018 Purchase 174 9.7600 € 1,698.24 € XPAR Cancellation  
21/05/2018 Purchase 17 9.7600 € 165.92 € XPAR Cancellation  
21/05/2018 Purchase 568 9.7400 € 5,532.32 € XPAR Cancellation  
21/05/2018 Purchase 30 9.7500 € 292.50 € XPAR Cancellation  
21/05/2018 Purchase 285 9.7500 € 2,778.75 € XPAR Cancellation  
21/05/2018 Purchase 314 9.7400 € 3,058.36 € XPAR Cancellation  
21/05/2018 Purchase 109 9.7400 € 1,061.66 € XPAR Cancellation  
21/05/2018 Purchase 10 9.7400 € 97.40 € XPAR Cancellation  
21/05/2018 Purchase 433 9.7300 € 4,213.09 € XPAR Cancellation  
21/05/2018 Purchase 421 9.7200 € 4,092.12 € XPAR Cancellation  
21/05/2018 Purchase 53 9.7100 € 514.63 € XPAR Cancellation  
21/05/2018 Purchase 230 9.7100 € 2,233.30 € XPAR Cancellation  
21/05/2018 Purchase 604 9.7000 € 5,858.80 € XPAR Cancellation  
21/05/2018 Purchase 165 9.7000 € 1,600.50 € XPAR Cancellation  
21/05/2018 Purchase 823 9.6900 € 7,974.87 € XPAR Cancellation  
21/05/2018 Purchase 645 9.6700 € 6,237.15 € XPAR Cancellation  
21/05/2018 Purchase 274 9.6400 € 2,641.36 € XPAR Cancellation  
21/05/2018 Purchase 183 9.6400 € 1,764.12 € XPAR Cancellation  
21/05/2018 Purchase 44 9.6400 € 424.16 € XPAR Cancellation  
21/05/2018 Purchase 454 9.6100 € 4,362.94 € XPAR Cancellation  
21/05/2018 Purchase 54 9.6000 € 518.40 € XPAR Cancellation  
21/05/2018 Purchase 264 9.6000 € 2,534.40 € XPAR Cancellation  
21/05/2018 Purchase 623 9.5800 € 5,968.34 € XPAR Cancellation  
21/05/2018 Purchase 563 9.6000 € 5,404.80 € XPAR Cancellation  
21/05/2018 Purchase 745 9.6000 € 7,152.00 € XPAR Cancellation  
21/05/2018 Purchase 222 9.6300 € 2,137.86 € XPAR Cancellation  
21/05/2018 Purchase 145 9.6300 € 1,396.35 € XPAR Cancellation  
21/05/2018 Purchase 193 9.6300 € 1,858.59 € XPAR Cancellation  
21/05/2018 Purchase 186 9.6300 € 1,791.18 € XPAR Cancellation  
21/05/2018 Purchase 331 9.6600 € 3,197.46 € XPAR Cancellation  
21/05/2018 Purchase 32 9.6600 € 309.12 € XPAR Cancellation  
21/05/2018 Purchase 3 9.6700 € 29.01 € XPAR Cancellation  
21/05/2018 Purchase 236 9.6700 € 2,282.12 € XPAR Cancellation  
21/05/2018 Purchase 104 9.6700 € 1,005.68 € XPAR Cancellation  
21/05/2018 Purchase 308 9.6700 € 2,978.36 € XPAR Cancellation  
21/05/2018 Purchase 9 9.6700 € 87.03 € XPAR Cancellation  
21/05/2018 Purchase 350 9.6900 € 3,391.50 € XPAR Cancellation  
21/05/2018 Purchase 230 9.6900 € 2,228.70 € XPAR Cancellation  
21/05/2018 Purchase 350 9.6900 € 3,391.50 € XPAR Cancellation  
21/05/2018 Purchase 230 9.6900 € 2,228.70 € XPAR Cancellation  
*Total 21/05/2018* *18,330* *9.7013 €* *177,824 €* *XPAR* *Cancellation*  
22/05/2018 Purchase 664 10.4000 € 6,905.60 € XPAR Cancellation  
22/05/2018 Purchase 100 10.4000 € 1,040.00 € XPAR Cancellation  
22/05/2018 Purchase 15 10.4000 € 156.00 € XPAR Cancellation  
22/05/2018 Purchase 85 10.4000 € 884.00 € XPAR Cancellation  
22/05/2018 Purchase 401 10.3800 € 4,162.38 € XPAR Cancellation  
22/05/2018 Purchase 157 10.3800 € 1,629.66 € XPAR Cancellation  
22/05/2018 Purchase 182 10.3800 € 1,889.16 € XPAR Cancellation  
22/05/2018 Purchase 250 10.3800 € 2,595.00 € XPAR Cancellation  
22/05/2018 Purchase 161 10.3800 € 1,671.18 € XPAR Cancellation  
22/05/2018 Purchase 205 10.3800 € 2,127.90 € XPAR Cancellation  
22/05/2018 Purchase 155 10.3800 € 1,608.90 € XPAR Cancellation  
22/05/2018 Purchase 330 10.4000 € 3,432.00 € XPAR Cancellation  
22/05/2018 Purchase 12 10.4000 € 124.80 € XPAR Cancellation  
22/05/2018 Purchase 279 10.4000 € 2,901.60 € XPAR Cancellation  
22/05/2018 Purchase 306 10.3800 € 3,176.28 € XPAR Cancellation  
22/05/2018 Purchase 112 10.3600 € 1,160.32 € XPAR Cancellation  
22/05/2018 Purchase 545 10.3600 € 5,646.20 € XPAR Cancellation  
22/05/2018 Purchase 291 10.3800 € 3,020.58 € XPAR Cancellation  
22/05/2018 Purchase 112 10.3800 € 1,162.56 € XPAR Cancellation  
22/05/2018 Purchase 26 10.3800 € 269.88 € XPAR Cancellation  
22/05/2018 Purchase 198 10.3800 € 2,055.24 € XPAR Cancellation  
22/05/2018 Purchase 119 10.3800 € 1,235.22 € XPAR Cancellation  
22/05/2018 Purchase 20 10.3800 € 207.60 € XPAR Cancellation  
22/05/2018 Purchase 271 10.3800 € 2,812.98 € XPAR Cancellation  
22/05/2018 Purchase 89 10.3800 € 923.82 € XPAR Cancellation  
22/05/2018 Purchase 10 10.3800 € 103.80 € XPAR Cancellation  
22/05/2018 Purchase 192 10.3800 € 1,992.96 € XPAR Cancellation  
22/05/2018 Purchase 426 10.3400 € 4,404.84 € XPAR Cancellation  
22/05/2018 Purchase 117 10.3600 € 1,212.12 € XPAR Cancellation  
22/05/2018 Purchase 15 10.3600 € 155.40 € XPAR Cancellation  
22/05/2018 Purchase 125 10.3800 € 1,297.50 € XPAR Cancellation  
22/05/2018 Purchase 216 10.3800 € 2,242.08 € XPAR Cancellation  
22/05/2018 Purchase 145 10.3800 € 1,505.10 € XPAR Cancellation  
22/05/2018 Purchase 12 10.3800 € 124.56 € XPAR Cancellation  
22/05/2018 Purchase 169 10.3800 € 1,754.22 € XPAR Cancellation  
22/05/2018 Purchase 81 10.3800 € 840.78 € XPAR Cancellation  
22/05/2018 Purchase 3 10.3800 € 31.14 € XPAR Cancellation  
22/05/2018 Purchase 223 10.3800 € 2,314.74 € XPAR Cancellation  
22/05/2018 Purchase 81 10.3800 € 840.78 € XPAR Cancellation  
22/05/2018 Purchase 33 10.3800 € 342.54 € XPAR Cancellation  
22/05/2018 Purchase 11 10.4000 € 114.40 € XPAR Cancellation  
22/05/2018 Purchase 343 10.4000 € 3,567.20 € XPAR Cancellation  
22/05/2018 Purchase 241 10.4200 € 2,511.22 € XPAR Cancellation  
22/05/2018 Purchase 121 10.4200 € 1,260.82 € XPAR Cancellation  
22/05/2018 Purchase 329 10.4200 € 3,428.18 € XPAR Cancellation  
22/05/2018 Purchase 360 10.4200 € 3,751.20 € XPAR Cancellation  
22/05/2018 Purchase 38 10.4200 € 395.96 € XPAR Cancellation  
22/05/2018 Purchase 2 10.4200 € 20.84 € XPAR Cancellation  
22/05/2018 Purchase 100 10.4200 € 1,042.00 € XPAR Cancellation  
22/05/2018 Purchase 291 10.4200 € 3,032.22 € XPAR Cancellation  
22/05/2018 Purchase 292 10.4200 € 3,042.64 € XPAR Cancellation  
22/05/2018 Purchase 124 10.4200 € 1,292.08 € XPAR Cancellation  
22/05/2018 Purchase 126 10.4200 € 1,312.92 € XPAR Cancellation  
22/05/2018 Purchase 11 10.4200 € 114.62 € XPAR Cancellation  
22/05/2018 Purchase 257 10.4200 € 2,677.94 € XPAR Cancellation  
22/05/2018 Purchase 243 10.4200 € 2,532.06 € XPAR Cancellation  
22/05/2018 Purchase 136 10.4200 € 1,417.12 € XPAR Cancellation  
22/05/2018 Purchase 284 10.4200 € 2,959.28 € XPAR Cancellation  
22/05/2018 Purchase 122 10.4200 € 1,271.24 € XPAR Cancellation  
22/05/2018 Purchase 252 10.4200 € 2,625.84 € XPAR Cancellation  
22/05/2018 Purchase 1 10.4200 € 10.42 € XPAR Cancellation  
22/05/2018 Purchase 165 10.4200 € 1,719.30 € XPAR Cancellation  
22/05/2018 Purchase 85 10.4200 € 885.70 € XPAR Cancellation  
22/05/2018 Purchase 300 10.4200 € 3,126.00 € XPAR Cancellation  
22/05/2018 Purchase 431 10.4200 € 4,491.02 € XPAR Cancellation  
22/05/2018 Purchase 269 10.4200 € 2,802.98 € XPAR Cancellation  
22/05/2018 Purchase 88 10.4200 € 916.96 € XPAR Cancellation  
22/05/2018 Purchase 556 10.4200 € 5,793.52 € XPAR Cancellation  
22/05/2018 Purchase 26 10.4200 € 270.92 € XPAR Cancellation  
22/05/2018 Purchase 212 10.4000 € 2,204.80 € XPAR Cancellation  
22/05/2018 Purchase 327 10.4000 € 3,400.80 € XPAR Cancellation  
22/05/2018 Purchase 129 10.4000 € 1,341.60 € XPAR Cancellation  
22/05/2018 Purchase 321 10.4000 € 3,338.40 € XPAR Cancellation  
22/05/2018 Purchase 100 10.4000 € 1,040.00 € XPAR Cancellation  
22/05/2018 Purchase 202 10.4000 € 2,100.80 € XPAR Cancellation  
22/05/2018 Purchase 82 10.4000 € 852.80 € XPAR Cancellation  
22/05/2018 Purchase 231 10.4000 € 2,402.40 € XPAR Cancellation  
22/05/2018 Purchase 309 10.4000 € 3,213.60 € XPAR Cancellation  
22/05/2018 Purchase 294 10.3800 € 3,051.72 € XPAR Cancellation  
22/05/2018 Purchase 186 10.3800 € 1,930.68 € XPAR Cancellation  
22/05/2018 Purchase 102 10.3800 € 1,058.76 € XPAR Cancellation  
22/05/2018 Purchase 80 10.3800 € 830.40 € XPAR Cancellation  
22/05/2018 Purchase 304 10.3800 € 3,155.52 € XPAR Cancellation  
22/05/2018 Purchase 141 10.3800 € 1,463.58 € XPAR Cancellation  
22/05/2018 Purchase 171 10.3800 € 1,774.98 € XPAR Cancellation  
22/05/2018 Purchase 754 10.3600 € 7,811.44 € XPAR Cancellation  
22/05/2018 Purchase 145 10.3400 € 1,499.30 € XPAR Cancellation  
22/05/2018 Purchase 167 10.3400 € 1,726.78 € XPAR Cancellation  
22/05/2018 Purchase 286 10.3600 € 2,962.96 € XPAR Cancellation  
*Total 22/05/2018* *17,080* *10.3928 €* *177,509 €* *XPAR* *Cancellation*  
23/05/2018 Purchase 675 10.3200 € 6,966.00 € XPAR Cancellation  
23/05/2018 Purchase 188 10.3000 € 1,936.40 € XPAR Cancellation  
23/05/2018 Purchase 155 10.3000 € 1,596.50 € XPAR Cancellation  
23/05/2018 Purchase 360 10.1400 € 3,650.40 € XPAR Cancellation  
23/05/2018 Purchase 425 10.1400 € 4,309.50 € XPAR Cancellation  
23/05/2018 Purchase 323 10.1600 € 3,281.68 € XPAR Cancellation  
23/05/2018 Purchase 292 10.1400 € 2,960.88 € XPAR Cancellation  
23/05/2018 Purchase 80 10.1800 € 814.40 € XPAR Cancellation  
23/05/2018 Purchase 292 10.1600 € 2,966.72 € XPAR Cancellation  
23/05/2018 Purchase 94 10.1600 € 955.04 € XPAR Cancellation  
23/05/2018 Purchase 572 10.1400 € 5,800.08 € XPAR Cancellation  
23/05/2018 Purchase 98 10.1400 € 993.72 € XPAR Cancellation  
23/05/2018 Purchase 381 10.1200 € 3,855.72 € XPAR Cancellation  
23/05/2018 Purchase 418 10.1000 € 4,221.80 € XPAR Cancellation  
23/05/2018 Purchase 607 10.0800 € 6,118.56 € XPAR Cancellation  
23/05/2018 Purchase 10 10.0800 € 100.80 € XPAR Cancellation  
23/05/2018 Purchase 225 10.0800 € 2,268.00 € XPAR Cancellation  
23/05/2018 Purchase 302 10.0800 € 3,044.16 € XPAR Cancellation  
23/05/2018 Purchase 293 10.1000 € 2,959.30 € XPAR Cancellation  
23/05/2018 Purchase 300 10.0800 € 3,024.00 € XPAR Cancellation  
23/05/2018 Purchase 425 10.0800 € 4,284.00 € XPAR Cancellation  
23/05/2018 Purchase 294 10.1000 € 2,969.40 € XPAR Cancellation  
23/05/2018 Purchase 27 10.0800 € 272.16 € XPAR Cancellation  
23/05/2018 Purchase 301 10.0600 € 3,028.06 € XPAR Cancellation  
23/05/2018 Purchase 67 10.1000 € 676.70 € XPAR Cancellation  
23/05/2018 Purchase 125 10.1000 € 1,262.50 € XPAR Cancellation  
23/05/2018 Purchase 171 10.1000 € 1,727.10 € XPAR Cancellation  
23/05/2018 Purchase 249 10.1000 € 2,514.90 € XPAR Cancellation  
23/05/2018 Purchase 168 10.1000 € 1,696.80 € XPAR Cancellation  
23/05/2018 Purchase 210 10.1000 € 2,121.00 € XPAR Cancellation  
23/05/2018 Purchase 12 10.1000 € 121.20 € XPAR Cancellation  
23/05/2018 Purchase 78 10.1000 € 787.80 € XPAR Cancellation  
23/05/2018 Purchase 47 10.1000 € 474.70 € XPAR Cancellation  
23/05/2018 Purchase 247 10.1000 € 2,494.70 € XPAR Cancellation  
23/05/2018 Purchase 314 10.0600 € 3,158.84 € XPAR Cancellation  
23/05/2018 Purchase 300 10.0600 € 3,018.00 € XPAR Cancellation  
23/05/2018 Purchase 304 10.0800 € 3,064.32 € XPAR Cancellation  
23/05/2018 Purchase 491 10.0600 € 4,939.46 € XPAR Cancellation  
23/05/2018 Purchase 602 10.0600 € 6,056.12 € XPAR Cancellation  
23/05/2018 Purchase 28 10.0600 € 281.68 € XPAR Cancellation  
23/05/2018 Purchase 302 10.0400 € 3,032.08 € XPAR Cancellation  
23/05/2018 Purchase 884 10.0600 € 8,893.04 € XPAR Cancellation  
23/05/2018 Purchase 367 10.0600 € 3,692.02 € XPAR Cancellation  
23/05/2018 Purchase 74 10.0600 € 744.44 € XPAR Cancellation  
23/05/2018 Purchase 276 10.0600 € 2,776.56 € XPAR Cancellation  
23/05/2018 Purchase 88 10.0600 € 885.28 € XPAR Cancellation  
23/05/2018 Purchase 356 10.0600 € 3,581.36 € XPAR Cancellation  
23/05/2018 Purchase 132 10.0600 € 1,327.92 € XPAR Cancellation  
23/05/2018 Purchase 421 10.0600 € 4,235.26 € XPAR Cancellation  
23/05/2018 Purchase 109 10.0600 € 1,096.54 € XPAR Cancellation  
23/05/2018 Purchase 64 10.0600 € 643.84 € XPAR Cancellation  
23/05/2018 Purchase 333 10.0600 € 3,349.98 € XPAR Cancellation  
23/05/2018 Purchase 378 10.0600 € 3,802.68 € XPAR Cancellation  
23/05/2018 Purchase 344 10.0600 € 3,460.64 € XPAR Cancellation  
23/05/2018 Purchase 344 10.0600 € 3,460.64 € XPAR Cancellation  
23/05/2018 Purchase 299 10.0600 € 3,007.94 € XPAR Cancellation  
23/05/2018 Purchase 45 10.0600 € 452.70 € XPAR Cancellation  
23/05/2018 Purchase 344 10.0600 € 3,460.64 € XPAR Cancellation  
23/05/2018 Purchase 335 10.0600 € 3,370.10 € XPAR Cancellation  
23/05/2018 Purchase 9 10.0600 € 90.54 € XPAR Cancellation  
23/05/2018 Purchase 140 10.0600 € 1,408.40 € XPAR Cancellation  
23/05/2018 Purchase 344 10.0600 € 3,460.64 € XPAR Cancellation  
23/05/2018 Purchase 17 10.0600 € 171.02 € XPAR Cancellation  
23/05/2018 Purchase 1 10.0600 € 10.06 € XPAR Cancellation  
23/05/2018 Purchase 343 10.0600 € 3,450.58 € XPAR Cancellation  
23/05/2018 Purchase 301 10.0600 € 3,028.06 € XPAR Cancellation  
23/05/2018 Purchase 410 10.0600 € 4,124.60 € XPAR Cancellation  
*Total 23/05/2018* *17,610 €* *10.0960 €* *177,791 €* *XPAR* *Cancellation*  
24/05/2018 Purchase 363 9.6400 € 3,499.32 € XPAR Cancellation  
24/05/2018 Purchase 288 9.6500 € 2,779.20 € XPAR Cancellation  
24/05/2018 Purchase 9 9.6500 € 86.85 € XPAR Cancellation  
24/05/2018 Purchase 31 9.6500 € 299.15 € XPAR Cancellation  
24/05/2018 Purchase 389 9.7400 € 3,788.86 € XPAR Cancellation  
24/05/2018 Purchase 205 9.7400 € 1,996.70 € XPAR Cancellation  
24/05/2018 Purchase 248 9.7400 € 2,415.52 € XPAR Cancellation  
24/05/2018 Purchase 8 9.7900 € 78.32 € XPAR Cancellation  
24/05/2018 Purchase 353 9.7900 € 3,455.87 € XPAR Cancellation  
24/05/2018 Purchase 200 9.7900 € 1,958.00 € XPAR Cancellation  
24/05/2018 Purchase 151 9.7900 € 1,478.29 € XPAR Cancellation  
24/05/2018 Purchase 440 9.7700 € 4,298.80 € XPAR Cancellation  
24/05/2018 Purchase 461 9.7900 € 4,513.19 € XPAR Cancellation  
24/05/2018 Purchase 39 9.7900 € 381.81 € XPAR Cancellation  
24/05/2018 Purchase 272 9.7900 € 2,662.88 € XPAR Cancellation  
24/05/2018 Purchase 518 9.7600 € 5,055.68 € XPAR Cancellation  
24/05/2018 Purchase 656 9.7300 € 6,382.88 € XPAR Cancellation  
24/05/2018 Purchase 303 9.7300 € 2,948.19 € XPAR Cancellation  
24/05/2018 Purchase 169 9.7600 € 1,649.44 € XPAR Cancellation  
24/05/2018 Purchase 295 9.7600 € 2,879.20 € XPAR Cancellation  
24/05/2018 Purchase 310 9.7600 € 3,025.60 € XPAR Cancellation  
24/05/2018 Purchase 27 9.7600 € 263.52 € XPAR Cancellation  
24/05/2018 Purchase 328 9.7700 € 3,204.56 € XPAR Cancellation  
24/05/2018 Purchase 112 9.7600 € 1,093.12 € XPAR Cancellation  
24/05/2018 Purchase 299 9.7600 € 2,918.24 € XPAR Cancellation  
24/05/2018 Purchase 295 9.7600 € 2,879.20 € XPAR Cancellation  
24/05/2018 Purchase 102 9.7600 € 995.52 € XPAR Cancellation  
24/05/2018 Purchase 317 9.7600 € 3,093.92 € XPAR Cancellation  
24/05/2018 Purchase 128 9.7600 € 1,249.28 € XPAR Cancellation  
24/05/2018 Purchase 174 9.7600 € 1,698.24 € XPAR Cancellation  
24/05/2018 Purchase 17 9.7600 € 165.92 € XPAR Cancellation  
24/05/2018 Purchase 568 9.7400 € 5,532.32 € XPAR Cancellation  
24/05/2018 Purchase 30 9.7500 € 292.50 € XPAR Cancellation  
24/05/2018 Purchase 285 9.7500 € 2,778.75 € XPAR Cancellation  
24/05/2018 Purchase 314 9.7400 € 3,058.36 € XPAR Cancellation  
24/05/2018 Purchase 109 9.7400 € 1,061.66 € XPAR Cancellation  
24/05/2018 Purchase 10 9.7400 € 97.40 € XPAR Cancellation  
24/05/2018 Purchase 433 9.7300 € 4,213.09 € XPAR Cancellation  
24/05/2018 Purchase 421 9.7200 € 4,092.12 € XPAR Cancellation  
24/05/2018 Purchase 53 9.7100 € 514.63 € XPAR Cancellation  
24/05/2018 Purchase 230 9.7100 € 2,233.30 € XPAR Cancellation  
24/05/2018 Purchase 604 9.7000 € 5,858.80 € XPAR Cancellation  
24/05/2018 Purchase 165 9.7000 € 1,600.50 € XPAR Cancellation  
24/05/2018 Purchase 823 9.6900 € 7,974.87 € XPAR Cancellation  
24/05/2018 Purchase 645 9.6700 € 6,237.15 € XPAR Cancellation  
24/05/2018 Purchase 274 9.6400 € 2,641.36 € XPAR Cancellation  
24/05/2018 Purchase 183 9.6400 € 1,764.12 € XPAR Cancellation  
24/05/2018 Purchase 44 9.6400 € 424.16 € XPAR Cancellation  
24/05/2018 Purchase 454 9.6100 € 4,362.94 € XPAR Cancellation  
24/05/2018 Purchase 54 9.6000 € 518.40 € XPAR Cancellation  
24/05/2018 Purchase 264 9.6000 € 2,534.40 € XPAR Cancellation  
24/05/2018 Purchase 623 9.5800 € 5,968.34 € XPAR Cancellation  
24/05/2018 Purchase 563 9.6000 € 5,404.80 € XPAR Cancellation  
24/05/2018 Purchase 745 9.6000 € 7,152.00 € XPAR Cancellation  
24/05/2018 Purchase 222 9.6300 € 2,137.86 € XPAR Cancellation  
24/05/2018 Purchase 145 9.6300 € 1,396.35 € XPAR Cancellation  
24/05/2018 Purchase 193 9.6300 € 1,858.59 € XPAR Cancellation  
24/05/2018 Purchase 186 9.6300 € 1,791.18 € XPAR Cancellation  
24/05/2018 Purchase 331 9.6600 € 3,197.46 € XPAR Cancellation  
24/05/2018 Purchase 32 9.6600 € 309.12 € XPAR Cancellation  
24/05/2018 Purchase 3 9.6700 € 29.01 € XPAR Cancellation  
24/05/2018 Purchase 236 9.6700 € 2,282.12 € XPAR Cancellation  
24/05/2018 Purchase 104 9.6700 € 1,005.68 € XPAR Cancellation  
24/05/2018 Purchase 308 9.6700 € 2,978.36 € XPAR Cancellation  
24/05/2018 Purchase 9 9.6700 € 87.03 € XPAR Cancellation  
24/05/2018 Purchase 350 9.6900 € 3,391.50 € XPAR Cancellation  
24/05/2018 Purchase 230 9.6900 € 2,228.70 € XPAR Cancellation  
24/05/2018 Purchase 350 9.6900 € 3,391.50 € XPAR Cancellation  
24/05/2018 Purchase 230 9.6900 € 2,228.70 € XPAR Cancellation  
*Total 24/05/2018* *18,330* *9.7013 €* *177,824 €* *XPAR* *Cancellation*  
25/05/2018 Purchase 125 9.7300 € 1,216.25 € XPAR Cancellation  
25/05/2018 Purchase 21 9.7300 € 204.33 € XPAR Cancellation  
25/05/2018 Purchase 2 9.8300 € 19.66 € XPAR Cancellation  
25/05/2018 Purchase 280 9.8300 € 2,752.40 € XPAR Cancellation  
25/05/2018 Purchase 342 9.8300 € 3,361.86 € XPAR Cancellation  
25/05/2018 Purchase 292 9.8200 € 2,867.44 € XPAR Cancellation  
25/05/2018 Purchase 160 9.8200 € 1,571.20 € XPAR Cancellation  
25/05/2018 Purchase 395 9.7800 € 3,863.10 € XPAR Cancellation  
25/05/2018 Purchase 25 9.7700 € 244.25 € XPAR Cancellation  
25/05/2018 Purchase 297 9.8100 € 2,913.57 € XPAR Cancellation  
25/05/2018 Purchase 485 9.8100 € 4,757.85 € XPAR Cancellation  
25/05/2018 Purchase 317 9.7800 € 3,100.26 € XPAR Cancellation  
25/05/2018 Purchase 421 9.7600 € 4,108.96 € XPAR Cancellation  
25/05/2018 Purchase 390 9.7700 € 3,810.30 € XPAR Cancellation  
25/05/2018 Purchase 361 9.7700 € 3,526.97 € XPAR Cancellation  
25/05/2018 Purchase 311 9.7800 € 3,041.58 € XPAR Cancellation  
25/05/2018 Purchase 109 9.7900 € 1,067.11 € XPAR Cancellation  
25/05/2018 Purchase 205 9.7900 € 2,006.95 € XPAR Cancellation  
25/05/2018 Purchase 395 9.8200 € 3,878.90 € XPAR Cancellation  
25/05/2018 Purchase 722 9.8300 € 7,097.26 € XPAR Cancellation  
25/05/2018 Purchase 313 9.8200 € 3,073.66 € XPAR Cancellation  
25/05/2018 Purchase 246 9.8200 € 2,415.72 € XPAR Cancellation  
25/05/2018 Purchase 68 9.8200 € 667.76 € XPAR Cancellation  
25/05/2018 Purchase 125 9.8100 € 1,226.25 € XPAR Cancellation  
25/05/2018 Purchase 266 9.8100 € 2,609.46 € XPAR Cancellation  
25/05/2018 Purchase 55 9.7900 € 538.45 € XPAR Cancellation  
25/05/2018 Purchase 309 9.7900 € 3,025.11 € XPAR Cancellation  
25/05/2018 Purchase 464 9.7700 € 4,533.28 € XPAR Cancellation  
25/05/2018 Purchase 449 9.7800 € 4,391.22 € XPAR Cancellation  
25/05/2018 Purchase 407 9.7200 € 3,956.04 € XPAR Cancellation  
25/05/2018 Purchase 407 9.7300 € 3,960.11 € XPAR Cancellation  
25/05/2018 Purchase 31 9.7200 € 301.32 € XPAR Cancellation  
25/05/2018 Purchase 49 9.7200 € 476.28 € XPAR Cancellation  
25/05/2018 Purchase 392 9.7300 € 3,814.16 € XPAR Cancellation  
25/05/2018 Purchase 182 9.7200 € 1,769.04 € XPAR Cancellation  
25/05/2018 Purchase 200 9.7200 € 1,944.00 € XPAR Cancellation  
25/05/2018 Purchase 373 9.7300 € 3,629.29 € XPAR Cancellation  
25/05/2018 Purchase 1 9.7300 € 9.73 € XPAR Cancellation  
25/05/2018 Purchase 266 9.7300 € 2,588.18 € XPAR Cancellation  
25/05/2018 Purchase 167 9.7300 € 1,624.91 € XPAR Cancellation  
25/05/2018 Purchase 29 9.7300 € 282.17 € XPAR Cancellation  
25/05/2018 Purchase 250 9.7300 € 2,432.50 € XPAR Cancellation  
25/05/2018 Purchase 339 9.7300 € 3,298.47 € XPAR Cancellation  
25/05/2018 Purchase 412 9.7100 € 4,000.52 € XPAR Cancellation  
25/05/2018 Purchase 397 9.7000 € 3,850.90 € XPAR Cancellation  
25/05/2018 Purchase 428 9.7000 € 4,151.60 € XPAR Cancellation  
25/05/2018 Purchase 680 9.6700 € 6,575.60 € XPAR Cancellation  
25/05/2018 Purchase 434 9.6900 € 4,205.46 € XPAR Cancellation  
25/05/2018 Purchase 139 9.6900 € 1,346.91 € XPAR Cancellation  
25/05/2018 Purchase 61 9.6900 € 591.09 € XPAR Cancellation  
25/05/2018 Purchase 321 9.6800 € 3,107.28 € XPAR Cancellation  
25/05/2018 Purchase 46 9.6800 € 445.28 € XPAR Cancellation  
25/05/2018 Purchase 791 9.7100 € 7,680.61 € XPAR Cancellation  
25/05/2018 Purchase 347 9.6900 € 3,362.43 € XPAR Cancellation  
25/05/2018 Purchase 50 9.6900 € 484.50 € XPAR Cancellation  
25/05/2018 Purchase 311 9.6600 € 3,004.26 € XPAR Cancellation  
25/05/2018 Purchase 459 9.6600 € 4,433.94 € XPAR Cancellation  
25/05/2018 Purchase 314 9.6700 € 3,036.38 € XPAR Cancellation  
25/05/2018 Purchase 463 9.6600 € 4,472.58 € XPAR Cancellation  
25/05/2018 Purchase 136 9.6600 € 1,313.76 € XPAR Cancellation  
25/05/2018 Purchase 86 9.7000 € 834.20 € XPAR Cancellation  
25/05/2018 Purchase 83 9.7100 € 805.93 € XPAR Cancellation  
25/05/2018 Purchase 251 9.7100 € 2,437.21 € XPAR Cancellation  
25/05/2018 Purchase 27 9.7100 € 262.17 € XPAR Cancellation  
25/05/2018 Purchase 951 9.7100 € 9,234.21 € XPAR Cancellation  
*Total 25/05/2018* *18,230* *9.7430 €* *177,614 €* *XPAR* *Cancellation*  
*TOTAL 21/05/2018 - 25/05/2018* *89,580* *9.9192 €* *888,563 €* *XPAR* *Cancellation*  
*CONTACTS ANALYSTS / INVESTORS*

* *
Thomas JACQUET
T. +33 (0)1 49 02 12 58
thomas.jacquet@coface.com

* *

* *

* *

* * Ana Cecilia URIBE ARCE DE BREANT
T. +33 (0)1 49 02 22 40
anacecilia.uribearce@coface.com

* *

*FINANCIAL CALENDAR 2018 **(subject to change)*
H1-2018 results: July 26^th 2018, before market opening
9M-2018 results: October 24^th 2018, after market close

*FINANCIAL INFORMATION*
This press release, as well as COFACE SA's integral regulatory information, can be found on the Group's website: http://www.coface.com/Investors

For regulated information on Alternative Performance Measures (APM),
please refer to our Interim Financial Report for S1-2017 and our 2017 Registration Document

* *

*Coface: for trade - Building business together*
70 years of experience and the most finely meshed network have made Coface a reference in credit insurance, risk management and the global economy.  With the ambition to become the most agile, global trade credit insurance partner in the industry, Coface's experts work to the beat of the world economy, supporting 50,000 clients in building successful, growing and dynamic businesses. The Group's services and solutions protect and help companies take credit decisions to improve their ability to sell on both their domestic and export markets. In 2017, Coface employed ~4,100 people in 100 countries and registered turnover of
€1.4 billion.

www,coface,com

COFACE SA est cotée sur le Compartiment A d'Euronext Paris

Code ISIN : FR0010667147 / Mnémonique : COFA

 
* *
^[1] Also in pursuant to Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (and updates); Article L.225-209 and seq. of the French Commercial Code; Article L.221-3, Article L.241-1 and seq. of the General Regulation of the French Market Authority (AMF); AMF Recommendation DOC-2017-04 Guide for issuers on their own shares transactions and for stabilization measures.

*Attachment*

· 2018 05 28 Declaration EN.pdf Reported by GlobeNewswire 2 hours ago.

KELOWNA, British Columbia, May 28, 2018 (GLOBE NEWSWIRE) -- The Thompson-Okanagan Development Region (Thompson-Okanagan) enjoyed a stellar performance in 2017, highlighted by a 10-year record in population growth, strong tourism activity, and record housing sales. Together, these factors stimulated job creation, particularly in the service sector.“Employment in 2017 reached an all-time high of 259,700 positions. Almost all of the jobs created last year were in the service sector, as seven of the 11 service industries recorded job gains,” said Karen Christiansen, FCPA, FCA, partner at MNP LLP. “This is not surprising, given the population growth, real estate demand, and tourism activity we experienced. For example, over half of the 12,000 new residents settled in the Okanagan-Similkameen Regional District, which led to increased service demand and tremendous growth in their real estate market. In Penticton, sales transactions were up 16 per cent to reach $544 million, and the average price for a single-family detached home jumped 19.4 per cent to $545,000 in 2017.”

In total, the service sector added 10,400 new positions. This growth completely offset the loss of 5,400 service jobs in 2016 and pushed service sector employment in the region to its highest level since 2012. Housing activity led to an increase of 3,400 new positions in the finance, insurance, real estate and leasing industry last year. Public administration followed with 2,500 job gains, while the retail trade industry added 1,800 positions, and the business, building and other support services industry added 1,500.

Employment in the Thompson-Okanagan’s goods sector grew by 1,000 jobs in 2017. Not surprisingly, construction saw the highest gain with 4,000 new jobs as housing starts ramped up. Despite challenging weather conditions that led to lower crop yields, the agriculture industry also added 400 positions. Forestry, logging and support services increased by 800 positions, but this gain was offset by an equal number of job losses in mining and oil and gas extraction. The latter likely relates to ripple effects from Alberta’s oil and gas sector as local mining production was stable in 2017 apart from minor closures due to the forest fires.

Despite the impressive job gains the region had last year, the Thompson-Okanagan’s unemployment rate remained high, at 7.1 per cent, or two percentage points above the provincial average. This seemingly lackluster performance is disguised by the 10,300 people who entered the workforce last year, including the re-entry of 4,800 people who had previously opted out of the labour market, indicating optimism in the job market.

“Over the first three months of 2018, we’ve seen our unemployment rate go back up slightly to 7.4 per cent, as employment declined,” said Christiansen, “We have yet to see our region’s seasonal surge in the spring/summer months as tourist and agricultural activity pick up. With the long winter we just had and the flooding threat we are under right now, seasonal employment activity may be further delayed.”

*About CPABC Regional Check-Up – Thompson-Okanagan*

The Thompson-Okanagan Development Region comprises five Regional Districts, the Okanagan-Similkameen, Thompson-Nicola, Central Okanagan, North Okanagan, and Columbia-Shuswap, and has the third-highest population after Southwest B.C. and Vancouver Island/Coast.

The CPABC Regional Check-Up reports look at British Columbia’s eight Development Regions as a place to work, invest, and live. The reports are available online at: www.bccheckup.com.  

*About CPA British Columbia*
The Chartered Professional Accountants of British Columbia (CPABC) is the training, governing, and regulatory body for over 35,000 CPA members and almost 5,000 CPA students. CPABC carries out its primary mission to protect the public by enforcing the highest professional and ethical standards and contributing to the advancement of public policy. CPAs are recognized internationally for bringing superior financial expertise, strategic thinking, business insight, and leadership to organizations.

CONTACT: For more information or to arrange an interview, contact:
Vivian Tse, Public Affairs Manager
604.488.2647
vtse@bccpa.ca Reported by GlobeNewswire 2 hours ago.

The oceanfront estate in San Clemente that was once owned by Richard M. Nixon and known as the Western White House during his presidency is back up for sale at $63.5 million — down from its $75-million asking price three years ago.

The seller is former Allergan Pharmaceuticals Chief Executive Gavin... Reported by L.A. Times 1 hour ago.

Gareth Bale's wondergoal has no doubt raised his price-tag, which probably makes him too much of a gamble for Manchester United this summer. Reported by Football FanCast 55 minutes ago.

Fans of NW Contemporary and mid-century modern design, rejoice. This home, a short walk from the Sound, offers all that plus spectacular water views, with a price tag of $894,950. Reported by SeattlePI.com 56 minutes ago.

Liverpool could be in pole position to snap up an Inter Milan starlet for just €8million this summer, a report claims

The post Path clear for Liverpool to seal cut price €8m deal for Inter Milan starlet appeared first on teamtalk.com. Reported by Team Talk 43 minutes ago.

CNG price in the national capital hiked by Rs 1.36 per kg on Monday as input raw material got costlier because of rupee depreciation and rise in natural gas price.

CNG will cost Rs 41.97 per kg in Delhi with effect from midnight following the price increase, Indraprastha Gas Ltd said in a statement.

In adjoining Noida, Greater Noida and Ghaziabad, rates were increased by Rs 1.55 to Rs 48.60 per kg.

The increase was warranted "to offset the impact on its input costs as a result of recent appreciation of dollar vis-a-vis rupee and revision in proportions of domestic gas allocation," the statement said.

IGL said it will continue to offer a discount of Rs 1.50 per kg in the selling prices of CNG for filling between 12.30 am to 5.30 am at select outlets. Thus, the consumer price of CNG would be Rs 40.47 per kg in Delhi and Rs 47.10 per kg in Noida, Greater Noida and Ghaziabad during 12.30 am to 5.30 am at the select CNG stations across the region.

Price of piped cooking gas hasn't been revised.

"There has been a steep appreciation of the dollar as compared to rupee since the last CNG price revision. The base price of natural gas being procured by IGL from its sources is dollar linked thereby making the entire input price totally dependent on price of dollar vis-a-vis rupee," it said.

IGL said the increase would have a marginal impact on the per km running cost of vehicles. For autos, the increase would be 4 paise per km, for taxi it would be 7 paise per km and in case of buses, the increase would be nearly 40 paise per km.

"With the revised price, CNG would still offer over 60 per cent savings towards the running cost when compared to petrol driven vehicles at the current level of prices. When compared to diesel driven vehicles, the economics in favour of CNG at revised price would be nearly 40 per cent," the statement added.

Article Type: 
Report
Sections: 
Business
Agencies: 
PTI
Tags: 
CNG
CNG rates
CNG prices
CNG rates in Delhi
CNG price rise
Indraprastha Gas Ltd
Tue, 29 May 2018-12:13am
Date updated: 
Tuesday, 29 May 2018 - 12:15am
Article Images: 
Short URL: 
dnai.in/2
Embargo: 
Syndicate: 
Hide lead image: 
Page views: 
1
From Print Edition: 
Highlights:  Reported by DNA 11 minutes ago.

Despite the pledge of Emmerson Mnangagwa's administration to end cash shortages and right the economy, the desperation shown by companies and consumers in Zimbabwe point to a different reality. Reported by News24 41 minutes ago.

After beating earnings and having the shares price fall, investors need to seriously consider investing in Canadian Imperial Bank of Commerce (TSX:CM)(NYSE:CM). Reported by Motley Fool 13 minutes ago.

Despite high price volatility, cryptocurrencies remain popular in Germany, especially among young people Reported by The Cointelegraph 1 hour ago.

Investors with losses of $100,000 or more are encouraged to contact the firm.LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the* June 4, 2018 *deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX) securities between *March 23, 2017, and April 2, 2018*, inclusive (the “Class Period”).To obtain information or actively participate in the class action, please visit the Cancer Genetics page on our website at www.glancylaw.com/case/cancer-genetics-inc.

Investors suffering losses on their Cancer Genetics investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.  

On April 2, 2018, the Company reported that following the departure of its former CEO, it undertook a “comprehensive and extensive review” of its strategy and organization. As a result, the Company recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable in the fourth quarter of 2017, largely related to “collection issues” with respect to the accounts receivable recorded subsequent to the Company’s 2015 acquisition of Response Genetics Inc. The Company further disclosed that it “had a Material Weakness in Internal Controls Over Financial Reporting at December 31, 2017” and that its 2017 annual report would contain a going concern qualification.

On this news, Cancer Genetics’ share price fell $0.55 per share, or 33.3%, thereby injuring investors.

The complaint filed in this class action alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares Cancer Genetics during the Class Period you may move the Court no later than * June 4, 2018 *to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

*Contacts*
Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
www.glancylaw.com 
shareholders@glancylaw.com Reported by GlobeNewswire 2 hours ago.

Investors with losses of $100,000 or more are encouraged to contact the firm

BENSALEM, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors of the *May 29, 2018 *deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Patterson Companies, Inc. (“Patterson” or the “Company”) (NASDAQ:PDCO) securities between *June 26, 2015 and February 28, 2018, *inclusive (the “Class Period”). Patterson investors have until *May 29, 2018 *to file a lead plaintiff motion.Investors suffering losses on their Patterson investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

The complaint filed in this class action alleges that the Company issued false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a fraudulent and illegal price-fixing conspiracy; (2) Patterson's revenue and earnings were fraudulently inflated by the illegal scheme; (3) the scheme was aimed at prohibiting sales to and price negotiations by group purchasing organizations which represented small and independent dental practices; (4) as a result, defendants' statements about Patterson's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

On February 12, 2018, the Federal Trade Commission (“FTC”) filed a complaint against certain dental supply companies, including Patterson, claiming that they violated U.S. antitrust laws by conspiring to refuse to provide discounts to, or otherwise serve, buying groups representing dental practitioners. On this news, Patterson’s share price fell $7.47 per share, or 23.6%, thereby injuring investors.

If you purchased shares of Patterson during the Class Period you may move the Court no later than *May 29, 2018 *to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

*Contacts*
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com Reported by GlobeNewswire 2 hours ago.

New e-commerce website, Blocktonic, lets consumers worldwide purchase more than 100 products, such as electronics, with CyberMiles Tokens (CMT)

Hong Kong, May 29, 2018 (GLOBE NEWSWIRE) -- CyberMiles (CMT), a public blockchain protocol designed and optimized for commercial applications, has launched an online marketplace that is among the first e-commerce platforms to support cryptocurrency only. Blocktonic.io, which exclusively accepts the CyberMiles Token (CMT) as a payment method, offers more than 60 products including electronics and the CMT Cube, CyberMiles’ new mining machine.

Initially, every product that consumers can buy on the Blocktonic website is essentially free because payments will be refunded over an extended period of time under a spending cashback program. Under the program, Blocktonic the purchase price in full Blocktonic also will offer a 100 percent rebate within a year to buyers who use CMT to purchase the CMT Cube. Additionally, Blocktonic shoppers can earn referral bonuses when they invite their friends to shop on the marketplace. 

“We are excited to introduce the first blockchain (crypto-only) e-commerce site,” Dr. Lucas Lu, founder of the CyberMiles Foundation, said. “Blockchain technology promises to revolutionize e-commerce, and we are confident Blocktonic is a step toward that, enriching the CyberMiles ecosystem with real application.”

With customer satisfaction the site’s top priority, Blocktonic is committed to providing a convenient ordering system with the highest-quality products for shoppers worldwide. The Blocktonic website is currently available in three languages: English, Korean, and Vietnamese, with additional language versions now in the works. 

Blocktonic is part of CyberMiles, which plans to subsidize Blocktonic’s marketing expenses. The spending cashback program is for limited number of products and for a limited time. For program terms and conditions, visit blocktonic.io/content/spending. To view and purchase products on Bloctonic, visit blocktonic.io today.

*Note: CyberMiles Token, known as CMT, should not to be confused with Comet Coin, also listed on some crypto exchanges as CMT. 

*About CyberMiles *

CyberMiles is a new decentralized blockchain protocol specifically designed and optimized for online marketplaces (like Ethereum for e-commerce). Initiated in 2017 by 5xlab, a blockchain development laboratory, and incorporated in Hong Kong as the non-profit organization CyberMiles Foundation, CyberMiles uses innovative “smart business contract” modules to facilitate and process transactions simply, effectively and with transparency. This technology focuses on commercial applications with protocols that ensure the appropriate balance between vertical effectiveness and network compatibility. 

With the spring 2018 release of its “Travis” TestNet, CyberMiles is on track to provide a strong alternative choice for Ethereum application developers, particularly for decentralized e-commerce apps. CyberMiles expects to release its MainNet in the second half of 2018, with more milestones to come in the interim. To learn more about the CyberMiles blockchain network, go to cybermiles.io.

*Attachment*

· 5e6b55fa-933e-4477-b05c-b8d1e7ff132a

CONTACT: Mark Brinkerhoff
CyberMiles
+1 (817) 681-5739
mark@cybermiles.io Reported by GlobeNewswire 2 hours ago.

· *Bayer, a German pharmaceutical and chemical company, has won approval from the US Justice Department to buy agricultural giant Monsanto.*
· *But farmers are worried about what the consolidation might mean for prices and their future business.*
· *Whereas Bayer and Monsanto claim the move will spur innovation, other analysts have expressed skepticism. *

--------------------

A blockbuster deal between Bayer and Monsanto is moving ahead.

Under a proposed settlement filed on Tuesday, Bayer agreed to sell its seed and herbicide businesses to German chemical company BASF — a move the US Department of Justice required for the deal's approval.

Bayer and Monsanto first announced the $60 billion deal in September 2016, saying the move would boost agriculture research and innovation.

"By the time 2050 rolls around, the world will have 10 billion people, and the demand for food will double," Robb Fraley, Monsanto's outgoing chief technology officer, told Business Insider last year. "The whole point here is that the business combination between Monsanto and Bayer will allow the companies to invest in and create more innovation, and it's going to take a huge amount of innovation in order to double the world's food supply."

Farmers aren’t so sure.

“From my perspective, they're saying the exact opposite of what most people in the industry actually believe," Clay Govier, a farmer in central Nebraska, told Business Insider in January 2017. Govier is the fifth generation to work on his family farm of 3,000 acres, which primarily grows corn and soybeans. The farm has used Monsanto products for at least 12 years, and Govier's family expects seed and chemical prices to increase due to the merger.

That could put many small family farms in tough positions.

"I just sat down to chat with my banker the other day, and fortunately we're in a position that I don't think we're going to have to have a hard conversation when it comes to loans for next year," Govier said. "But he said there are a lot of guys out there that are going to have a really hard conversation."

*Consolidation on the rise*

According to the US Department of Agriculture, farm production in the US has consistently shifted away from smaller farms, to larger ones. Whereas just 15% of all cropland was held by farms with at least 2,000 acres in 1987, that percentage had jumped to 36% by 2012.

With the increasing consolidation of the agriculture supply industry (Monsanto-Bayer is the biggest of three major mergers — preceded by Dow-DuPont and Syngenta-ChemChina), Govier doesn't expect things to get easier anytime soon. 

"They're locking in their profit and they're cornering the market by getting bigger, not by creating new products," he said of Bayer and Monsanto. "They're just choking out the rest of the competition."

The size of the Bayer-Monsanto deal — it was the biggest merger announced in 2016 after AT&T and Time Warner — means the companies have to seek approval from regulators in 30 countries.

The deal has already gotten antitrust approval in the European Union. US approval was expected as well, given that the CEOs of Bayer and Monsanto, Werner Baumann and Hugh Grant, visited President Donald Trump before he took office and said in a statement that the three had a "very productive meeting" at Trump Tower.

Baumann and Grant suggested that Trump shared their view of the agriculture industry's need for innovation. To that end, the companies highlighted their plan to spend $16 billion on research and development worldwide over six years — an average of $2.67 billion a year.

But a look at their past R&D budgets reveals that, added up, the two companies already spent approximately $2.59 billion a year as of early 2017, so the combined increase in funds amounts to less than $500 million over six years.

"Let's just cut to the chase: These companies want to make more money, they want to raise prices," Mark Connelly, an agriculture analyst at the brokerage and investment group CLSA Americas, previously told Business Insider. "No company in this industry needs these deals in order to innovate."

*Higher costs for farmers*

Data compiled by the Farmers Business Network, a data-distribution network that collects crowd-sourced information from members, backs up Connelly's concern. FBN analyzed corn-seed yield (the number of bushels farmers can produce per acre) in relation to the seed brands' market share, based on data from 5.75 million acres of corn. It found that while greater market share was correlated with higher yield — a primary goal of agricultural innovation — the rise wasn't proportional.

"After you got to a few percent market share, it really tapered off quite quickly," FBN cofounder Charles Baron told Business Insider in 2017. "So going from 5 or 10% to 20 or 30% market share didn't lead to a massive yield increase."

When plotting seed prices in relation to market share, FBN data also showed that greater market dominance was correlated with higher corn seed and chemical prices.

That doesn't bode well for farmers, since the newly consolidated agricultural companies already make up a significant portion of the market, according to Connelly's analysis.

"If you look at how much of the farmers' seed and pesticide dollars are going to these companies, Monsanto-Bayer — if it were one company today — would be getting $1 out of every $3," Connelly says. "Dow-Dupont would be taking one out of every $4. Think that's a problem? Holy crap, right?"

Such consolidation isn't the only headache for farmers under the Trump administration. Some farm owners who depend on immigrant workers have concerns about Trump's immigration policies, since they say they can't find enough American citizens to fill their staffs. Agriculture industry groups also strongly opposed Trump's trade restrictions on China, since the country is likely to retaliate with high tariffs of its own. 

"We’ll make it up to them," Trump reportedly said on Monday, according to Politico. "The farmers will be better off than they ever were."

*Bayer and Monsanto's motivation to merge*

Bayer representatives acknowledged in a 2017 statement to Business Insider that they were often confronted with the allegation that the merger would raise prices and reduce innovation and competition.

"We disagree with this and are convinced the opposite is true," the company wrote. "We are competing with other very strong companies that offer similar products and have strong R&D capabilities. We will only succeed with pricing and selling our products if our value proposition to our customers is better than that of our competitors and if we continue to innovate. We are also convinced that in a competitive business such as the agriculture industry, the efficiency gains generated by innovation will increase returns for farmers."

Monsanto's Fraley estimated that, under the current system, it takes about a decade for a company to develop and get approval for a new herbicide. Then if that product is popular, it'll take the company another 10 years to make a seed trait that responds to the new chemical. But since Bayer and Monsanto's combined resources might allow them to develop paired products in tandem, he said they could halve the time it takes to bring those new products to farmers.

Connelly has a different hypothesis. Monsanto has historically sought out partnerships and joint ventures with other companies that are developing innovative products. But that means dividing up profits. So Connelly predicts the size of a combined Monsanto-Bayer will lead the new company to favor a mediocre product or solution that it can develop in-house over a more promising one that would require a revenue-sharing partnership.

"We're not going to be chasing the best solution anymore — we're going to be chasing the good-enough solution," Connelly said.

Todd Eney, a fourth-generation farmer in central Montana, previously told Business Insider that as suppliers of seeds and chemicals have become more consolidated, he hasn't seen many benefits.

"These corporate bigwigs, are they really going to do what they say?" he said. "Our farm has been out here since 1935, and I'm 40 years old and I've watched a lot of small family farms in our area go under. They can't compete because they can't pay the price of input because of what these companies are wanting to charge for input now."

Eney's farm grows wheat, malt barley, and field peas, and it uses Roundup, Monsanto's popular weed killer. Last year, he said, he and his father decided to use 50% less fertilizer to cut costs. The possibility of further consolidation has him on edge.

Clay Govier has a similar feeling.

"You know, it's almost like you shrug your shoulders and cross your fingers that your regulators are going to have a backbone and not let it happen,” he said last year.

That scenario does not seem to be playing out as he'd hoped. 

This is an updated version of a story originally published February 5, 2017. If you're a farmer or entrepreneur affected by this merger and would like to talk about its impact, please reach out to dvarinsky@businessinsider.com.

*SEE ALSO: Trump-supporting farmers are worried that new immigration policies would be a disaster*

Join the conversation about this story »

NOW WATCH: Octopuses are officially the weirdest animals on Earth Reported by Business Insider 2 hours ago.

Memorial Day weekend may be over, but fortunately you’ll still find some good deals lurking about. B&H, for example, is selling the current 27-inch 3.4GHz iMac with 5K Retina display for $250 off, which brings the price down to a considerably more agreeable $1,549 shipped. It’s the best deal we know of for this specific model at the moment.

To read this article in full, please click here Reported by Macworld 2 hours ago.

LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the* May 29, 2018 *deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) securities between *January 25, 2018, and March 14, 2018*, inclusive (the “Class Period”).To obtain information or actively participate in the class action, please visit the Solid Biosciences page on our website at www.glancylaw.com/case/solid-biosciences-inc.

Investors suffering losses on their Solid Biosciences investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.  

On January 30, 2018, an article was published by various medical experts highlighting the risks of studies using high doses of gene therapies using adeno-associated virus (AAV)-the delivery system used by Solid Biosciences’ lead drug candidate SGT-001. One of the article’s co-authors was Dr. James Wilson, a former member of the Solid Biosciences’ advisory board. On this news the Company’s shares fell $1.20 per share, or over 5%, to close on January 30, 2018 at $22.50 per share.

Then on March 14, 2018, the Company announced that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the SGT-001 Phase I/II clinical trial, IGNITE DMD, because of adverse events associated with the therapy. On this news, Solid Biosciences’ share price fell $16.99 per share, or over 60%, to close at $9.32 per share on March 15, 2018, thereby injuring investors.

The complaint filed in this class action alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, Defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects, were materially false and/or misleading.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares Solid Biosciences during the Class Period you may move the Court no later than* May 29, 2018 *to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

*Contacts*
Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
www.glancylaw.com 
shareholders@glancylaw.com Reported by GlobeNewswire 2 hours ago.

Bitcoin has surprised us all and jumped by approximately five percent in less than an hour. The cryptocurrency was trading for roughly $7,100 during the early morning of May 29, only to incur a spike that saw its price rise by over $300. This is good news, in the short-term… And yet, it appears the bulls are not making a valid and full appearance as of late. Bitcoin is roughly ten percent away from a solid buying mark should the bear sentiment remain as it is, though some analysts believe stronger (and renewed) sentiment will appear if bitcoin drops back Reported by The Merkle 1 hour ago.

· Global Atomic’s conflicted board has presided over substantial value destruction.

· CEO Stephen Roman’s attentions are divided while he continues to act as CEO of Harte Gold (TSX:HRT) in addition to his duties to Global Atomic.
· Global Atomic requires a board that can act as independent fiduciaries for shareholders.
· Vote the *BLUE* proxy to bring accountability to Global Atomic.

TORONTO, May 29, 2018 (GLOBE NEWSWIRE) -- Greyling Investments, Inc. (“Greyling”), which owns or controls 7,847,599 shares representing approximately 7.33% of the issued and outstanding shares of Global Atomic Corporation (“Global Atomic” or the “Company”) (TSXV:GLO), has nominated six highly-qualified candidates for election at the upcoming annual and special meeting of shareholders of Global Atomic to be held on June 20, 2018 (the “Meeting”). These individuals are: Basil Carter, Anne Day, Lisa Swartzman, Gary Love, William Wright and Murray Leitch.Yesterday, Greyling released a letter to fellow shareholders of Global Atomic and filed its proxy circular in connection with the Meeting. In its letter, Greyling expresses its significant concerns about the Company’s poor performance, heavily conflicted board of directors (the “Board”), lack of transparency and the Board’s ineffective management oversight. Greyling also highlights Global Atomic Chairman, President & CEO Stephen Roman’s track-record of destroying shareholder value at Global Atomic and other companies. Greyling is also concerned that Mr. Roman’s attentions are divided, since he is also employed as Chairman, President and CEO of Harte Gold Corporation (TSX:HRT) and receiving compensation from that company as well.

Greyling believes that the 40% drop^1 in the Company’s share price from the September 29, 2017 meeting of shareholders to May 22, 2018 is indicative of widespread shareholder discontent about the direction of the Company. As such, it had no alternative but to exercise its rights as a shareholder of the Company and nominate six individuals who could bring a much needed infusion of skills, experience and shareholder-focused perspective to the Board.

Greyling will mail proxy materials to shareholders in connection with the Meeting. Shareholders are encouraged to carefully review those materials. Greyling urges Global Atomic shareholders to discard any materials received from management and vote only on the *BLUE* Greyling proxy or voting instruction form, *FOR* all of its nominees.

The full text of the letter can be found at:

http://resource.globenewswire.com/Resource/Download/9049a84b-6e6b-4660-a6db-8db891c94333

If you have any questions, contact Greyling’s proxy solicitor, Evolution Proxy Inc., at 1-833-744-9230 toll-free in North America, or at 416-907-4204 outside of North America (collect calls accepted), or by e-mail at info@evolutionproxy.com.

A copy of the letter and proxy circular is available on Global Atomic’s company profile on SEDAR at www.sedar.com.

*Disclaimers *

Greyling has not sought or obtained consent from any third party to the use herein of previously published information. Any such information should not be viewed as indicating the support of such third party for the views expressed herein.

Except for the historical information contained herein, the matters addressed in these materials are forward-looking statements that involve certain risks and uncertainties. You should be aware that actual results could differ materially from those contained in the forward-looking statements. Greyling does not assume any obligation to update the forward-looking information.

*Source:* Greyling Investments, Inc.

*Investor Contact:*

Evolution Proxy, Inc.
1-833-744-9230 – North America
416-907-4204 – International
info@evolutionproxy.com

*Media Contact:*

Bayfield Strategy, Inc.
Riyaz Lalani
rlalani@bayfieldstrategy.com* *

^1 Based on closing price of September 28, 2017 – last business day before September 29, 2017 shareholder meeting and May 22, 2018 – last business day before Global Atomic filed its 2018 Management Information Circular.

  Reported by GlobeNewswire 1 hour ago.